Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. With experienced management and multiple upcoming ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

In this comprehensive guide, we will explore the PharmaZee GLP-1 program, including how it works, the pricing structure, the benefits, and common FAQs. GLP-1, or glucagon-like peptide-1 ...

JPMorgan says Pfizer’s (PFE) decision to discontinue development of danuglipron, an oral small molecule GLP-1, due to a liver toxicity issue in ...

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street ...

Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.